Instead, we're recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems ...

TScan Therapeutics Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company with a market capitalization of $139.57 million, is poised at a critical juncture in its development of innovative ...

Today, Plug's stock trades about 99% below its IPO price. It also slumped about 10% over the past 12 months as investors ...

Senior analysts from AM Best will review proposed updates to its draft criteria procedure, "Rating Captives and Other ...

We recently compiled a list of the 10 Best Russell 2000 Stocks to Invest in According to Analysts. In this article, we are ...

To compile our list of the Best Hydrogen and Fuel Cell Stocks to Buy, we started with companies that have a significant presence in the hydrogen and fuel cell industry. We sifted through ETFs and ...

L'Oreal's Cell BioPrint, unveiled at CES 2025, is designed to take the mystery and frustration out of choosing skin care ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

CMN-005 is under clinical development by Benecyte and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition ...

Learn more The best cell phone plans offer enough data for ... more affordable than the least expensive plans from its parent company, T-Mobile; see our guide to Mint Mobile vs.

Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.